Polymyalgia Rheumatica (PMR): Symptoms, Diagnosis, and Treatment

What is Polymyalgia Rheumatica (PMR)?

Polymyalgia rheumatica (PMR) is a chronic inflammatory condition characterized by pain, stiffness, and reduced range of motion in the large proximal muscle groups, specifically affecting:

• Shoulders, neck, and upper arms
• Buttocks, hips, and thighs

PMR is one of the most common inflammatory rheumatic diseases in older adults, yet it remains frequently underdiagnosed or misdiagnosed, particularly in its early stages when it may resemble other common conditions.

Association with Giant Cell Arteritis

An important feature of PMR is its well-established clinical association with giant cell arteritis (GCA), also known as Horton’s temporal arteritis. This is an autoimmune vasculitis that affects medium and large blood vessels, with a predilection for the arteries of the head and neck (particularly the temporal arteries, located on the sides of the skull).

• Approximately 15–20% of patients with PMR also have GCA
• Conversely, up to 50% of patients with GCA have concurrent PMR

This association is clinically critical because GCA requires a significantly more aggressive treatment approach (higher doses of corticosteroids) compared to PMR alone, and because GCA carries serious risks such as permanent vision loss and stroke if untreated. Therefore, the concurrent presence of GCA must always be actively ruled out in any patient diagnosed with PMR.

Overview of Clinical Features

The clinical presentation of PMR is characterized by:

• Bilateral muscle pain and stiffness, especially in the shoulder girdle and pelvic girdle
• Morning stiffness, often lasting more than 45 minutes
• Functional impairment and reduced ability to perform daily activities
• Fatigue and general malaise
• Loss of appetite and unintentional weight loss
• Fever
• Headache, sometimes accompanied by scalp tenderness

Treatment Goals

Treatment aims to control muscle pain, improve stiffness, and resolve associated systemic symptoms. The mainstay of therapy is low-dose corticosteroid medication (such as prednisone), maintained over a prolonged period of approximately one to two years with gradual dose reduction.

---

Can It Be Cured?

The prognosis for polymyalgia rheumatica is generally favorable. The disease responds remarkably well to corticosteroid therapy, and most patients experience dramatic symptom relief within 24 to 72 hours of initiating treatment. This response is so characteristic that it is itself considered a diagnostic indicator of the disease.

Key prognostic points:

• Most patients achieve remission with appropriate treatment
• Relapse is possible, particularly if corticosteroids are reduced too rapidly; the tapering schedule must always be slow, gradual, and closely monitored
• Long-term management (often 1–2 years or more) may be required in some patients
• Overall, PMR allows for near-complete recovery of normal quality of life in the majority of patients with adherence to treatment

---

Causes

The exact cause of polymyalgia rheumatica remains unknown. However, a combination of genetic susceptibility and environmental triggers is believed to underlie the development of the condition.

Genetic Predisposition

• PMR has been associated with specific HLA (human leukocyte antigen) system antigens, particularly the HLA-DR4 and HLA-CW3 haplotypes
• A positive family history of PMR or other rheumatic/autoimmune diseases in first-degree relatives increases individual susceptibility

Environmental and Infectious Triggers

• The most studied hypothesis is that exposure to an unidentified infectious agent, most likely a viral pathogen affecting the respiratory tract, triggers an abnormal immune system activation in genetically predisposed individuals
• This leads to chronic inflammatory damage that over time produces the characteristic symptoms of PMR
• The seasonal clustering of PMR onset (more common in certain months) supports this infectious trigger hypothesis
• The inflammatory process is of autoimmune nature, meaning the immune system erroneously attacks the body’s own tissues

Epidemiology

• PMR is rare before the age of 50 and is almost exclusively a disease of older adults
• The majority of diagnoses are made in patients over 70 years of age
• It affects women more frequently than men, with an approximately 2–3:1 female-to-male ratio
• It is particularly prevalent in Northern European populations and individuals of Northern European descent
• Incidence estimates range from 12 to 68 cases per 100,000 people over 50 years of age per year, making it one of the most common inflammatory rheumatic conditions in the elderly

---

Symptoms

The symptoms of polymyalgia rheumatica can be divided into specific musculoskeletal symptoms, which form the diagnostic core of the condition, and nonspecific systemic symptoms.

Core Musculoskeletal Symptoms

Pain (Myalgia and Periarticular Pain)

• Pain is primarily muscular (myalgia), but also affects tendons, tendon sheaths, ligaments, and joints
• It is bilateral and symmetric, affecting both sides of the body equally
• It predominantly involves:
  • Neck and shoulder girdle (shoulders and upper arms)
  • Upper back and dorsal spine
  • Pelvic girdle, hips, and thighs
• Pain onset is often nocturnal or at rest, but characteristically worsens with movement and muscle contraction
• The pain tends to persist and become chronic if left untreated

Morning Stiffness

• Stiffness is particularly pronounced in the morning, typically lasting more than 45 minutes after waking (a key diagnostic criterion)
• It can be so severe that patients are unable to get out of bed unassisted, or experience extreme difficulty transitioning from prolonged sitting (e.g., after a long car or airplane journey) to standing
• Stiffness also worsens after any period of inactivity

Functional Impairment

• Patients may have significant difficulty performing routine daily activities, including:
  • Getting dressed (particularly raising arms above shoulder height)
  • Driving a vehicle
  • Cooking and household tasks
  • Grooming and personal hygiene
• Functional limitation is most pronounced in the shoulder girdle (affecting arm-to-body connection) and pelvic girdle (affecting leg-to-body connection)

Bursitis: An Important Associated Finding

Among the musculoskeletal structures affected in PMR, bursae (fluid-filled sacs that cushion friction between tissues and bones) play a central role. Their inflammation, termed “bursitis”, is a characteristic finding on ultrasound examination in PMR.

• Subdeltoid/subacromial bursitis: Bilateral inflammation of the bursae beneath the deltoid muscle and around the shoulder joint, which is the most characteristic finding in PMR
• Trochanteric bursitis: Bilateral inflammation of the bursae at the greater trochanter (upper outer thigh area)
• Bicipital tenosynovitis: Inflammation of the tendon of the long head of the biceps muscle and its surrounding tendon sheath, which is visible on ultrasound in virtually all PMR patients. It causes pain at rest and with muscle contraction, limiting elbow flexion and forearm rotation

These bursitic changes cause swelling, pain, and resulting functional impairment of the adjacent muscles and joints.

Systemic (Non-Specific) Symptoms

Alongside the core musculoskeletal features, PMR is often accompanied by:

• Severe fatigue is frequently the earliest symptom to appear, sometimes preceding musculoskeletal pain by weeks
• Loss of appetite and unintentional weight loss
• Weakness and general malaise
• Low-grade fever or high fever (pyrexia)
• Headache and scalp tenderness: particularly important as potential indicators of concurrent GCA
• Mood disturbances with a depressive-like presentation related to chronic pain, sleep disturbance, and the burden of systemic inflammation
• Jaw claudication: pain during meals and chewing (mastication), caused by ischemia of the masseter muscles. In severe cases, this can progress to paresis (partial loss of voluntary muscle activity). This symptom is a red flag for concurrent GCA and requires urgent evaluation.

---

When to See a Doctor

Like many rheumatological and autoimmune conditions, polymyalgia rheumatica is a complex condition to recognize and diagnose, and its chronic nature can be burdensome for patients.

Who to See First

If you experience symptoms resembling those described above, the first point of contact should be your General Practitioner (GP), who plays an important role in the initial diagnostic and therapeutic approach. Given the complexity of the condition and the need for ongoing management, referral to a specialist in Rheumatology is strongly advisable for confirmatory diagnosis, comprehensive investigations, and long-term treatment planning.

Why Early Evaluation Matters

• In the early stages, PMR may be mistakenly attributed to a post-viral (post-flu) syndrome, as the initial symptoms can be nonspecific
• Without correct treatment, symptoms will persist or progressively worsen
• The combination of proximal bilateral muscle pain, morning stiffness lasting more than 45 minutes, functional impairment, and elevated inflammatory markers in a patient over 50 should prompt urgent medical evaluation

Red Flag Symptoms Requiring Urgent Assessment

The following symptoms suggest possible concurrent giant cell arteritis (GCA) and require urgent medical attention (same-day or emergency evaluation):

• New or unusual headache, particularly temporal or occipital
• Scalp tenderness when touching or combing hair
• Visual disturbances (blurred vision, double vision, sudden vision loss): GCA can cause irreversible blindness if untreated
• Jaw claudication (pain during chewing)
• Tenderness or thickening of the temporal artery
• Sudden one-sided facial pain

---

Diagnosis

The diagnosis of polymyalgia rheumatica requires an integrated approach combining clinical history, physical examination, laboratory investigations, and imaging.

Medical History (Anamnesis)

A detailed medical history is essential. Key areas to explore include:

• Family history of PMR, rheumatoid arthritis, or other autoimmune/rheumatic conditions in first-degree relatives
• Characterization of pain: location, quality, bilateral symmetry, onset (gradual vs. sudden), aggravating and relieving factors, nocturnal onset
• Distribution of affected areas: shoulder girdle and/or pelvic girdle involvement
• History of trauma to the shoulder or hip
• Current and recent medications
• Previous surgical procedures
• Presence and duration of morning stiffness (> 45 minutes is diagnostically significant)

Physical Examination

The physician assesses:

• Range of motion in the shoulders, hips, and neck
• Tenderness on palpation of shoulder, neck, and hip muscles
• Signs of bursitis (localized swelling and tenderness)
• Temporal artery examination: tenderness, thickening, reduced or absent pulsation (GCA screening)
• General condition: fever, weight, lymph node assessment

Laboratory Investigations

Blood tests are an essential component of the diagnostic workup:

• Standard Complete Blood Count (CBC): May reveal normocytic or microcytic anemia, characteristic of chronic inflammatory disease
• Erythrocyte Sedimentation Rate (ESR/VES): Markedly elevated (often > 40–50 mm/hr, frequently > 100 mm/hr); ESR is also used as a disease activity marker during follow-up
• C-Reactive Protein (CRP/PCR): Elevated; a sensitive but non-specific inflammatory marker
• Alkaline Phosphatase (ALP): May be mildly elevated
• Rheumatoid Factor (RF): Negative in PMR (positive in ~70% of rheumatoid arthritis patients); helps exclude rheumatoid arthritis
• Anti-CCP antibodies: Also negative in PMR; more specific than RF for rheumatoid arthritis exclusion
• Creatine Phosphokinase (CPK): Normal in PMR. This is an important distinguishing feature from conditions that cause true muscle fiber damage (e.g., polymyositis, inflammatory myopathies), in which CPK is significantly elevated
• Comprehensive autoantibody panel: Including ANA, anti-dsDNA, ANCA, and others to exclude other autoimmune conditions (such as lupus or vasculitis)
• Thyroid function tests: Hypothyroidism can mimic PMR symptoms
• Serum protein electrophoresis: To exclude myeloma

Imaging: Ultrasound

Musculoskeletal ultrasound of the shoulder and pelvic girdles has become the most important first-line imaging tool in PMR diagnosis. It can identify:

• Subdeltoid/subacromial bursitis (bilateral)
• Bicipital tenosynovitis (present in virtually all PMR patients)
• Trochanteric bursitis (bilateral)
• Hip joint synovitis

These findings, when bilateral and present in the characteristic distribution, are highly supportive of the PMR diagnosis and are now incorporated into modern classification criteria.

MRI may be used in complex or atypical cases, and shows similar findings with greater anatomical detail, particularly for detecting axial involvement.

Temporal Artery Biopsy

Temporal artery biopsy is indicated in patients who present with symptoms, even mild ones, suggestive of concurrent giant cell arteritis (GCA), such as headache, scalp tenderness, jaw claudication, or visual symptoms. It remains the gold standard for confirming GCA diagnosis.

Summary of Key Diagnostic Criteria for PMR

The following elements support a diagnosis of PMR:

• Age > 50 years (virtually mandatory)
• Bilateral shoulder girdle pain and stiffness (and/or pelvic girdle)
• Morning stiffness lasting > 45 minutes
• Markedly elevated ESR and/or CRP
• Chronic anemia (typically microcytic, as seen in chronic inflammatory disease)
• Normal CPK (ruling out primary muscle disease)
• Negative RF and anti-CCP antibodies (ruling out rheumatoid arthritis)
• Headache and scalp tenderness (requires GCA exclusion)
• Fever with malaise and weight loss
• Jaw claudication (rare, but raises concern for concurrent GCA)
• Symptom persistence for at least 1 month without treatment
• Exclusion of other diagnoses (see differential diagnosis below)
• Dramatic and rapid response to low-dose corticosteroids, considered one of the most reliable diagnostic indicators

Differential Diagnosis

The clinical picture of PMR overlaps significantly with many other conditions, making differential diagnosis essential:

• Gout and pseudogout (crystal-induced arthritis)
• Osteoarthritis (arthrosis) is very common in the elderly
• Mechanical trauma or sports injuries
• Rheumatoid arthritis (particularly late-onset RA, or LORA) can closely mimic PMR
• Systemic Lupus Erythematosus (SLE)
• Ankylosing spondylitis
• Lyme disease
• Sarcoidosis
• Fibromyalgia shares many symptomatic features with PMR but differs in inflammatory markers (ESR and CRP are normal in fibromyalgia)
• Inflammatory myopathies (polymyositis, dermatomyositis): differentiated by elevated CPK and muscle biopsy findings
• Multiple myeloma and other hematological malignancies
• Solid malignant tumors may have paraneoplastic syndromes that mimic PMR
• Hypothyroidism can cause proximal muscle weakness and pain with elevated ESR
• Infectious conditions, including viral myalgias and bacterial endocarditis

---

Treatment

The therapeutic approach to polymyalgia rheumatica is primarily pharmacological, supported by physiotherapy and rehabilitation cycles as adjuncts.

A correct and promptly initiated treatment regimen typically produces remarkable clinical improvement within the first 48–72 hours, with a rapidity and magnitude of response that is itself considered highly characteristic of PMR.

Pharmacological Treatment

1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

NSAIDs (such as ibuprofen, naproxen, or diclofenac) may be used in the acute phase for symptomatic relief of pain and joint/muscle inflammation. However, they are generally considered insufficient as monotherapy for PMR and are primarily used as adjuncts or in very mild cases while awaiting specialist evaluation.

2. Corticosteroids (Prednisone / Prednisolone)

Corticosteroids are the cornerstone of PMR treatment and produce rapid, dramatic symptom relief. Current guidelines recommend:

• Starting dose: Prednisone 12.5 to 25 mg/day (commonly 15 mg/day), which is sufficient to achieve remission in most patients without initial dose escalation
• The dose is not increased simply because inflammatory markers (e.g., ESR) rise without a corresponding worsening of clinical symptoms; dose increases are reserved for cases of clear clinical deterioration
• Tapering schedule: Once symptoms are well-controlled (typically after 2–4 weeks), the dose is slowly and carefully reduced, usually by no more than 1–2.5 mg per month, titrated to the lowest dose that maintains remission
• Total treatment duration: At least 12 to 24 months; premature discontinuation is the most common cause of relapse
• If corticosteroids fail to produce a significant response, the diagnosis of PMR should be seriously reconsidered, as dramatic steroid responsiveness is a hallmark of the condition

Important: Because PMR predominantly affects older patients who may already have risk factors for osteoporosis, diabetes, hypertension, and cataracts, long-term corticosteroid use must be carefully monitored for side effects (see bone protection below).

3. Steroid-Sparing Agents (Methotrexate and Azathioprine)

Methotrexate and azathioprine are immunosuppressive agents used as steroid-sparing therapy in selected patients:

• Those with frequent relapses during corticosteroid tapering
• Those with high disease activity requiring persistently elevated corticosteroid doses
• Those experiencing significant corticosteroid-related side effects

These agents allow corticosteroid doses to be reduced while maintaining disease control, significantly improving quality of life and reducing long-term steroid toxicity.

4. Tocilizumab (IL-6 Receptor Inhibitor)

Tocilizumab, an interleukin-6 (IL-6) receptor inhibitor, has shown efficacy in relapsing or refractory PMR in clinical trials and is approved for use in GCA. In some patients with difficult-to-control PMR, it may be considered by the specialist as part of a biologic therapy approach.

5. Bone Protection Medications

Long-term corticosteroid use significantly increases the risk of osteoporosis. This is a major concern in older PMR patients. Preventive therapy should be initiated at the start of corticosteroid treatment and includes:

• Bisphosphonates (e.g., alendronate, risedronate, or zoledronic acid): The primary pharmacological intervention for corticosteroid-induced osteoporosis prevention
• Vitamin D supplementation: Essential for maintaining bone metabolism; frequently deficient in older adults
• Calcium supplementation: To support bone density and neuromuscular function
• DEXA scan (bone densitometry): Recommended at baseline and periodically during treatment to monitor bone density

Additional monitoring recommendations during corticosteroid therapy include regular checks of:

• Blood pressure (risk of hypertension)
• Blood glucose (risk of steroid-induced diabetes)
• Weight
• Intraocular pressure (risk of glaucoma)
• Lipid profile

Rest or Exercise: Which Is Better?

This is a common and important question from patients with PMR.

Regular, moderate physical activity is strongly recommended for PMR patients, except during acute flares characterized by marked joint stiffness and pain. The benefits of exercise include:

• Preservation of muscle mass (muscle trophism), particularly important given that corticosteroids themselves can cause muscle wasting (steroid myopathy) with prolonged use
• Maintenance and improvement of joint mobility and range of motion
• Improved cardiovascular health and metabolic function
• Mood enhancement and reduction of depression-related symptoms associated with chronic disease

An exercise program should be tailored to the individual patient in collaboration with the rheumatologist and physiotherapist, taking into account the current disease phase, functional limitations, and comorbidities.

Adequate rest is equally important, allowing the body to recover from both physical activity and daily life demands. The key principle is to find a sustainable balance between activity and rest, avoiding both excessive sedentariness and overexertion.

Physiotherapy and rehabilitation cycles are a valuable complement to pharmacological treatment, helping to:

• Restore shoulder and hip range of motion
• Strengthen periarticular muscles
• Improve posture and body mechanics
• Reduce the risk of falls (particularly relevant in older patients)

---

Sources and Bibliography

• Harrison’s Principles of Internal Medicine, 17th Edition. McGraw Hill.
• Potestà. Manuale di Diagnostica e Terapia Medica, 11th Edition. Verduci.
• MedScape: Polymyalgia Rheumatica
• Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases. 2015;74(10):1799-1807.
• Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442-2458.
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. The Lancet. 2008;372(9634):234-245.
• Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases. 2012;71(4):484-492.
• NHS: Polymyalgia rheumatica
• American College of Rheumatology: Polymyalgia Rheumatica
• NIH MedlinePlus: Polymyalgia Rheumatica